Tracking the rise in venture funding for gene, cell therapy companies: Data Byte

2020 was the biggest year yet for seed and series A funding of biotechs developing gene and cell therapies, with a 38% jump in total amount raised over the previous high water mark of 2018.

Following a trickle of initial approvals, interest in cell and gene therapies has exploded. FDA’s Center for Biologics Evaluation and Research (CBER) was tracking more than 900 INDs for gene therapies in 2020 and expects to be approving 10-20 cell and gene therapies per year by 2025, a massive jump over the two gene therapies FDA has approved since 2017...